Ovarian cancer is the seventh most common cancer in the world. It is also ranked as the eighth leading cause of cancer-related deaths among women and makes up around 4% of all cancer diagnoses in women. Every year, more than 310,000 women are diagnosed with ovarian cancer and around 200,000 women die from the disease. Survival rates have been improving but the progress is slow.
Ovarian Cancer Landscape Data
Though many investigational therapies are emerging, the diverse nature of Ovarian Cancer demands in-depth clinical investigation to develop effective treatments.
This article provides a detailed analysis of the current clinical trials landscape for Ovarian Cancer covering trial statuses, phases, geographical distributions, and patient demographics.
Ovarian Cancer Clinical Trials by Status
The Trialtrove database shows that out of 5,566 total ovarian cancer trials, just over 25% are actively recruiting or in progress.
Ovarian Cancer Trials by Status
Citeline Trialtrove® – 10MAY2024
Ovarian Cancer Trials by Start Date
The growth in ovarian cancer trials is evident with an increasing number of trials commencing each year, as detailed in the upcoming graph.
Planned & Ongoing Ovarian Cancer Trials by Start Date
Citeline Trialtrove® – 10MAY2024
Ovarian Cancer Trials by Country
With trials spread across 67 countries, ovarian cancer research is truly a global enterprise, with the United States and China hosting the vast majority of current trials.
Planned & Ongoing Ovarian Cancer Trials by Site Country
Chart Caption: Citeline Trialtrove® – 10MAY2024
Ovarian Cancer Trials by Patient Segment
Therapeutic strategies in ovarian cancer trials are broadly distributed, with 175 first-line trials, 935 second-line trials, and 609 including patients who are third line or greater. Looking at cancer stages, many ovarian cancers are focused on later stages. In fact, less than 7% of the ovarian cancer trials currently underway include Stage 1 or Stage 2 patients.
Planned & Ongoing Ovarian Cancer Trials by Line and Segment
Citeline Trialtrove® – 10MAY2024
Here, we also take a look at the subtypes of ovarian cancer. As evidenced by the chart below, over 200 current ovarian cancer clinical trials focus on HER2 negative ovarian cancer followed by squamous cell ovarian cancer. This is important because some treatments target specific proteins. HER2-positive treatments are only effective in patients with HER2-positive cancer.
Planned & Ongoing Ovarian Cancer Trials by Subtype
Citeline Trialtrove® – 10MAY2024
Ovarian Cancer Trials by Phase
Phase analysis indicates a heavy focus on early development, with almost 87% of current ovarian cancer trials being Phase 1, Phase 1-2 or Phase 2, showing the exploratory nature of ovarian oncology research.
Planned & Ongoing Ovarian Cancer Trials by Phase
Citeline Trialtrove® – 10MAY2024
Precision's Expertise in Ovarian Cancer Research
At the cutting edge of ovarian cancer research, Precision for Medicine has initiated 37 trials, focusing on novel therapeutic approaches.
Ovarian Cancer Trial Starts
Over the past five years, Precision for Medicine has launched 19 new ovarian cancer trials, each aimed at addressing critical gaps in current treatment paradigms.
Precision for Medicine's Ovarian Cancer Trials by Start Date
Citeline Trialtrove® – 10MAY2024
Precision's Reach in Ovarian Cancer Research
Precision for Medicine has established a robust network of ovarian cancer clinical trials in the leading countries for this type of oncology research, leveraging global diversity to drive innovation in treatment approaches.
Precision for Medicine's Ovarian Cancer Trials by Site Country
Citeline Trialtrove® – 10MAY2024
Trials by Phase
In ovarian cancer research, our clinical experience extends across Phase 1, Phase 1-2, and Phase 2 trials, demonstrating our commitment to developing foundational therapies from the ground up.
Precision for Medicine's Ovarian Cancer Trials by Phase
Citeline Trialtrove® – 10MAY2024
Precision's Experience by Patient Segment
Our research spans all patient segments in ovarian cancer clinical trials, conducting 7 trials for initial treatment, 33 for second line therapy, and 36 that are subsequent interventions. We have also worked with early-stage ovarian cancer as well as late stage.
Precision for Medicine's Ovarian Cancer Trials by Line and Segment
Citeline Trialtrove® – 10MAY2024
Precision Ovarian Cancer Trials by Subtype
Precision’s ovarian cancer experience includes various subtypes, from the more common HER2 negative ovarian cancer to mutations in the KRAS gene.
Precision for Medicine's Ovarian Cancer Trials by Subtype
Citeline Trialtrove® – 10MAY2024
The Precision Difference
Through strategic research initiatives in ovarian oncology research, Precision for Medicine is guiding the way for future therapies. This review highlights how active and diverse the current landscape of ovarian cancer clinical trials is, and shows that Precision has the experience to help you study thrive in this space.
